Alliancebernstein L.P. Alnylam Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 45,373 shares of ALNY stock, worth $12.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,373

Previous 54,176 16.25%

Holding current value

$12.5 Million

Previous $8.1 Million 36.18%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $1.26 Million - $2.17 Million	-8,803 Reduced 16.25%	45,373 $11 Million
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $68.4 Million - $92.5 Million	-466,663 Reduced 89.6%	54,176 $8.1 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $3.01 Million - $3.91 Million	-19,867 Reduced 3.67%	520,839 $99.7 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $1.63 Million - $2.03 Million	-9,573 Reduced 1.74%	540,706 $95.8 Million
Q2 2023 Aug 15, 2023	BUY	$185.01 - $212.05 $2.65 Million - $3.04 Million	14,320 Added 2.67%	550,279 $105 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $84.9 Million - $109 Million	464,775 Added 652.92%	535,959 $107 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $702,045 - $913,117	-3,784 Reduced 5.05%	71,184 $16.9 Million
Q3 2022 Nov 15, 2022	SELL	$138.54 - $232.0 $83.1 Million - $139 Million	-600,039 Reduced 88.89%	74,968 $15 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $74.5 Million - $105 Million	618,470 Added 1093.92%	675,007 $98.5 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $1.7 Million - $2.32 Million	-13,343 Reduced 19.09%	56,537 $9.23 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $509,634 - $668,472	3,194 Added 4.79%	69,880 $11.9 Million
Q3 2021 Nov 10, 2021	BUY	$169.75 - $207.73 $808,858 - $989,833	4,765 Added 7.7%	66,686 $12.6 Million
Q2 2021 Jul 30, 2021	SELL	$128.63 - $176.89 $745,796 - $1.03 Million	-5,798 Reduced 8.56%	61,921 $10.5 Million
Q1 2021 May 06, 2021	SELL	$126.83 - $175.69 $7.07 Million - $9.8 Million	-55,758 Reduced 45.16%	67,719 $9.56 Million
Q4 2020 Feb 08, 2021	BUY	$122.97 - $147.0 $6.97 Million - $8.33 Million	56,687 Added 84.87%	123,477 $16 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $1.32 Million - $1.8 Million	-10,901 Reduced 14.03%	66,790 $9.73 Million
Q2 2020 Aug 13, 2020	BUY	$104.21 - $156.44 $467,902 - $702,415	4,490 Added 6.13%	77,691 $11.5 Million
Q1 2020 May 14, 2020	SELL	$93.12 - $133.99 $5.08 Million - $7.31 Million	-54,587 Reduced 42.72%	73,201 $7.97 Million
Q4 2019 Feb 18, 2020	BUY	$74.51 - $124.23 $942,178 - $1.57 Million	12,645 Added 10.98%	127,788 $14.7 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $799,184 - $989,907	11,272 Added 10.85%	115,143 $9.26 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $3.63 Million - $5.11 Million	55,080 Added 112.89%	103,871 $7.54 Million
Q1 2019 May 14, 2019	SELL	$72.76 - $93.45 $14,479 - $18,596	-199 Reduced 0.41%	48,791 $4.56 Million
Q4 2018 Feb 13, 2019	SELL	$62.67 - $88.33 $43,743 - $61,654	-698 Reduced 1.4%	48,990 $3.57 Million
Q3 2018 Nov 08, 2018	SELL	$87.52 - $122.67 $143,532 - $201,178	-1,640 Reduced 3.2%	49,688 $4.35 Million
Q2 2018 Aug 13, 2018	BUY	$88.31 - $107.8 $180,593 - $220,451	2,045 Added 4.15%	51,328 $5.06 Million
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $443,973 - $568,908	3,830 Added 8.43%	49,283 $5.87 Million
Q4 2017 Feb 13, 2018	BUY	$114.49 - $139.98 $192,343 - $235,166	1,680 Added 3.84%	45,453 $5.78 Million
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $3.17 Million - $5.18 Million	43,773	43,773 $5.14 Million

Others Institutions Holding ALNY

# of Institutions

614

Shares Held

108M

Call Options Held

2.33M

Put Options Held

2.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Alnylam Pharmaceuticals, Inc. Transaction History